Indivior (NASDAQ:INDV) Director Purchases $27,427.25 in Stock

Indivior PLC (NASDAQ:INDV) Director Barbara Ryan purchased 775 shares of the stock in a transaction dated Monday, January 5th. The shares were acquired at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the acquisition, the director directly owned 1,963 shares of the company’s stock, valued at approximately $69,470.57. This trade represents a 65.24% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Indivior Trading Down 1.0%

INDV stock traded down $0.35 during trading on Wednesday, hitting $35.85. The company had a trading volume of 1,097,072 shares, compared to its average volume of 1,460,802. The business has a 50 day moving average of $33.69 and a 200 day moving average of $25.59. The firm has a market capitalization of $4.48 billion, a price-to-earnings ratio of 38.96 and a beta of 0.75. Indivior PLC has a fifty-two week low of $7.62 and a fifty-two week high of $38.00.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Thursday, October 30th. The company reported $0.72 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.34. The company had revenue of $314.00 million for the quarter, compared to the consensus estimate of $257.66 million. Indivior had a net margin of 9.83% and a negative return on equity of 90.79%. As a group, equities analysts predict that Indivior PLC will post 1.22 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Oaktree Capital Management LP grew its stake in Indivior by 2,241.6% during the 3rd quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock valued at $6,215,206,000 after acquiring an additional 246,776,273 shares in the last quarter. Divisadero Street Capital Management LP increased its stake in shares of Indivior by 2,372.5% in the third quarter. Divisadero Street Capital Management LP now owns 3,362,605 shares of the company’s stock worth $81,072,000 after acquiring an additional 3,226,605 shares during the last quarter. Goldentree Asset Management LP acquired a new position in shares of Indivior in the third quarter worth $42,630,000. Newtyn Management LLC raised its holdings in shares of Indivior by 61.1% during the third quarter. Newtyn Management LLC now owns 4,200,000 shares of the company’s stock worth $101,262,000 after acquiring an additional 1,592,982 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Indivior by 1,122.6% during the second quarter. Geode Capital Management LLC now owns 1,576,915 shares of the company’s stock valued at $23,244,000 after purchasing an additional 1,447,939 shares during the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Wall Street Analyst Weigh In

INDV has been the topic of a number of research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Indivior in a report on Friday, October 31st. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 3rd. Piper Sandler restated an “overweight” rating and issued a $41.00 target price (up from $27.00) on shares of Indivior in a report on Friday, October 31st. Northland Securities set a $40.00 target price on Indivior in a report on Friday, October 31st. Finally, Morgan Stanley reissued an “overweight” rating and issued a $36.00 price target on shares of Indivior in a research note on Wednesday, December 3rd. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $32.71.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.